The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The antibody was designed and developed at Abzena’s Cambridge, UK,
Subscribe To Our Newsletter & Stay Updated
